We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Nektar’s Immunotherapy Paired with BMS’ Blockbuster Opdivo Missed Key Endpoints in Melanoma Trial
Nektar’s Immunotherapy Paired with BMS’ Blockbuster Opdivo Missed Key Endpoints in Melanoma Trial
Nektar Therapeutics’ experimental immunotherapy bempegaldesleukin paired with Bristol Myers Squibb’s (BMS) blockbuster checkpoint inhibitor, Opdivo (nivolumab), did not shrink tumors, slow the growth of tumors or prolong survival rates for metastatic melanoma patients in a phase 3 trial in which the combo was compared to Opdivo alone.